Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer.
View/ Open
Date
2018-01-01Author
Lawler, M
Alsina, D
Adams, RA
Anderson, AS
Brown, G
Fearnhead, NS
Fenwick, SW
Halloran, SP
Hochhauser, D
Hull, MA
Koelzer, VH
McNair, AGK
Monahan, KJ
Näthke, I
Norton, C
Novelli, MR
Steele, RJC
Thomas, AL
Wilde, LM
Wilson, RH
Tomlinson, I
Bowel Cancer UK Critical Research Gaps in Colorectal Cancer Initiative,
Type
Journal Article
Metadata
Show full item recordAbstract
OBJECTIVE: Colorectal cancer (CRC) leads to significant morbidity/mortality worldwide. Defining critical research gaps (RG), their prioritisation and resolution, could improve patient outcomes. DESIGN: RG analysis was conducted by a multidisciplinary panel of patients, clinicians and researchers (n=71). Eight working groups (WG) were constituted: discovery science; risk; prevention; early diagnosis and screening; pathology; curative treatment; stage IV disease; and living with and beyond CRC. A series of discussions led to development of draft papers by each WG, which were evaluated by a 20-strong patient panel. A final list of RGs and research recommendations (RR) was endorsed by all participants. RESULTS: Fifteen critical RGs are summarised below: RG1: Lack of realistic models that recapitulate tumour/tumour micro/macroenvironment; RG2: Insufficient evidence on precise contributions of genetic/environmental/lifestyle factors to CRC risk; RG3: Pressing need for prevention trials; RG4: Lack of integration of different prevention approaches; RG5: Lack of optimal strategies for CRC screening; RG6: Lack of effective triage systems for invasive investigations; RG7: Imprecise pathological assessment of CRC; RG8: Lack of qualified personnel in genomics, data sciences and digital pathology; RG9: Inadequate assessment/communication of risk, benefit and uncertainty of treatment choices; RG10: Need for novel technologies/interventions to improve curative outcomes; RG11: Lack of approaches that recognise molecular interplay between metastasising tumours and their microenvironment; RG12: Lack of reliable biomarkers to guide stage IV treatment; RG13: Need to increase understanding of health related quality of life (HRQOL) and promote residual symptom resolution; RG14: Lack of coordination of CRC research/funding; RG15: Lack of effective communication between relevant stakeholders. CONCLUSION: Prioritising research activity and funding could have a significant impact on reducing CRC disease burden over the next 5 years.
Collections
Subject
Bowel Cancer UK Critical Research Gaps in Colorectal Cancer Initiative
Humans
Colorectal Neoplasms
Genetic Predisposition to Disease
Risk Factors
Evidence-Based Medicine
Biomedical Research
Early Detection of Cancer
Gene-Environment Interaction
Research team
Cancer Genomics
Translational Oncogenomics
Language
eng
Date accepted
2017-10-25
License start date
2018-01
Citation
Gut, 2018, 67 (1), pp. 179 - 193
Publisher
BMJ PUBLISHING GROUP
Except where otherwise noted, this item's license is described
as
https://creativecommons.org/licenses/by/4.0
Related items
Showing items related by title, author, creator and subject.
-
Quality assurance of dysphagia-optimised intensity modulated radiotherapy treatment planning for head and neck cancer.
Tyler, J; Bernstein, D; Seithel, M; Rooney, K; Petkar, I; et al. (ELSEVIER, 2021-10-01)This study aimed to assess the impact of the margin applied to the clinical target volume, to create the planning target volume, on plan quality of a novel dysphagia-optimised intensity modulated radiotherapy technique ... -
The UK plasma based molecular profiling of advanced breast cancer to inform therapeutic choices (plasmamatch) trial: a multiple parallel cohort, open-label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening (CRUK/15/010)
Bliss, J; Kernaghan, S; Fribbens, C; Stevenson, L; Morden, J; et al. (BIOMED CENTRAL LTD, 2017-05-08) -
Susceptibility loci of CNOT6 in the general mRNA degradation pathway and lung cancer risk-A re-analysis of eight GWASs.
Zhou, F; Wang, Y; Liu, H; Ready, N; Han, Y; et al. (WILEY, 2017-04-01)PURPOSE: mRNA degradation is an important regulatory step for controlling gene expression and cell functions. Genetic abnormalities involved in mRNA degradation genes were found to be associated with cancer risks. Therefore, ...